The third cluster consisted of 8 controls and 2 MS patients, who developed a high immune response in both parameters (higher than 3700 mlU/mL of SARS-CoV-2 IFN-γ and 800 AU/mL SARS-CoV-2 IgG). This evidence concerns the gene IFNG and myeloid sarcoma.